Edward L Briercheck, Shashidhar Ravishankar, Elshafa Hassan Ahmed, Cesar Camilo Carias Alvarado, Oscar Silva, Elizabeth Solórzano-Ortiz, Marcos Mauricio Siliezar Tala, Philip A Stevenson, Yuexin Xu, Anthony Wilder Wohns, Daniel Enriquez-Vera, Carlos Barrionuevo, Shan-Chi Yu, Aharon G Freud, Christoph Weigel, Christopher C Oakes, David M Weinstock, Haley L Klimaszewski, Apollinaire Ngankeu, Nora Mutalima, Gabriela Samayoa-Reyes, Robert Newton, Rosemary Rochford, Fabiola Valvert, Yasodha Natkunam, Andrei Shustov, Robert A Baiocchi, Edus H Warren
Epstein-Barr virus (EBV) is a potent carcinogen linked to hematologic and solid malignancies, causing significant global morbidity and mortality. Therapy using allogeneic EBV-specific lymphocytes shows promise in certain populations, but the impact of EBV genome variation on these strategies remains unexplored. To address this, we sequenced 217 EBV genomes, including hematologic malignancies from Guatemala, Peru, Malawi, and Taiwan, and analyzed them alongside 1,307 publicly available EBV genomes from cancer, non-malignant diseases, and healthy individuals across Africa, Asia, Europe, North America, and South America...
May 30, 2024: Blood Advances